-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $4

Benzinga·02/26/2026 20:23:25
Listen to the news
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $6 to $4.